One-year soy protein supplementation does not improve lipid profile in postmenopausal women

Menopause

Volumn 17, Issue 3, 2010, Pages 587-593

  Campbell, Sara Chelland ^a   Khalil, Dania A ^a   Payton, Mark E ^b   Arjmandi, Bahram H ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

^b OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Ferric reducing ability of plasma; Isoflavone; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN IGFBP 3; SOMATOMEDIN C; SOYBEAN PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; POSTMENOPAUSE; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HEART DISEASES; HUMANS; HYPERCHOLESTEROLEMIA; ISOFLAVONES; LIPIDS; MIDDLE AGED; POSTMENOPAUSE; SOYBEAN PROTEINS; TRIGLYCERIDES; WOMEN'S HEALTH;

EID: 77952293180     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181cb85d3     Document Type: Article

References (55)

1. Gordon T, Kanel WB, Hjortland MC, Mc Namara PM. Menopause and coronary heart disease. The Framingham study. Ann Intern Med 1978; 89:157-161.
2. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88:2404-2411.
3. Verhoeven MO, van der Mooren MJ, Teerlink T, Verheijen RH, Scheffer PG, Kenemans P. The influence of physiological and surgical menopause on coronary heart risk markers. Menopause 2009;16:37-49.
4. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971;74:1-12.
5. US Food and Drug Administration. Food labeling: health claims; soluble fiber from certain foods and coronary heart disease (psyllium husk); Final rule. Fed Reg 1998;63:8103-8121.
6. US Food and Drug Administration. Food labeling: health claims; soluble fiber from whole oats and risk of coronary heart disease; Final rule. Fed Reg 1997;62:3584-3601.
7. US Food and Drug Administration. Food labeling: health claims; soluble fiber from whole oats and risk of coronary heart disease; Final rule, clarification. Fed Reg 1997;62:15343-15344.
8. US Food and Drug Administration. Food labeling: health claims; soy protein and coronary heart disease; Final rule. Fed Reg 1999;64: 57699-57733.
9. Arjmandi BH, Smith BJ. Soy isoflavones osteoprotective role in post-menopausal women: mechanism of action. J Nutr Biochem 2002;13: 130-137.
10. Kurzer MS. Soy consumption for reduction of menopausal symptoms. Inflammopharmacology 2008;16:227-229.
11. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor A. Endocrinol 1998;139:4252-4263.
12. Gaddi A, Descovich GC, Noseda G, et al. Hypercholesterolaemia treated by soybean protein. Arch Dis Child 1987;63:274-278.
13. Grundy SM, Abrams JJ. Comparison of actions of soy protein and casein on metabolism of plasma lipoproteins and cholesterol in humans. Am J Clin Nutr 1983;38:245-252.
14. Goldberg AP, Lim A, Kolar JB, Grundhauser JJ, Steinke FH, Schonfeld G. Soybean protein independently lowers plasma cholesterol levels in primary hypercholesterolemia. Atherosclerosis 1982;43:355-368.
15. Wolfe BM, Giovannetti PM, Cheng DCH, Roberts DCK, Carroll KK. Hypolipidemic effects of substituting soybean protein isolate for all meat and dairy protein in the diets of hypercholesterolemic men. Nutr Rep Int 1981;24:1187-1198.
16. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995;333: 276-282.
17. Rios DRA, Rodrigues ET, Cardoso APZ, Montes MBA, Franceschini SA, Toloi MRT. Lack of effects of isoflavones on the lipid profile of Brazilian postmenopausal women. Nutrition 2008;24:1153-1158.
18. Shidfar F, Ehramphosh E, Heydari I, Haghighi L, Hosseini S, Shidfar S. Effects of soy bean on serum paraoxonase 1 activity and lipoproteins in hyperlipidemic postmenopausal women. Int J Food Sci Nutr 2008;19: 1-11.
19. Atteritano M, Marini H, Minutoli L, et al. Effects of the phytoes-trogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a 2-years randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2007;92:3068-3075.
20. Aubertin-Leheudre M, Lord C, Khalil A, Dionne IJ. Effect of 6 months of exercise and isoflavone supplementation on clinical cardiovascular risk factors in obese postmenopausal women: a randomized, double-blind study. Menopause 2007;14:624-629.
21. Ho SC, Chen YM, Ho SS, Woo JL. Soy isoflavone supplementation and fasting serum glucose and lipid profile among postmenopausal Chinese women: a double-blind, randomized, placebo-controlled trial. Menopause 2007;14:905-912.
22. Engelman HM, Alekel DL, Hanson LN, Kanthasamy AG, Reddy MB. Blood lipid and oxidative stress responses to soy protein with isofla-vones and phytic acid in postmenopausal women. Am J Clin Nutr 2005; 81:590-596.
23. Roughead ZK, Hunt JR, Johnson LK, Badger TM, Lykken GI. Controlled substitution of soy protein for meat protein: effects on calcium retention, bone, and cardiovascular health indices in postmenopausal women. J Clin Endocrinol Metab 2005;90:181-189.
24. Messina M, Lampe JW, Birt DF, et al. Reductionism and the narrowing nutrition perspective: time for reevaluation and emphasis on food synergy. J Am Diet Assoc 2001;101:1416-1419.
25. Arjmandi BH, Khan DA, Juma S, et al. Whole flaxseed consumption lowers serum LDL-cholesterol and lipoprotein(a) concentrations in postmenopausal women. Nutr Res 1998;18:1203-1214.
26. Arjmandi BH, Juma S, Lucas EA, Wei L, Venkatesh S, Khalil DA. Flaxseed supplementation positively influences bone metabolism in postmenopausal women. JAMA 1998;1:27-32.
27. Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of Bantioxidant power[: the FRAP assay. Anal Biochem 1996; 239:70-76.
28. Baird DD, Umbach DM, Lansdell L, et al. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women. J Clin Endocrinol Metab 1995;80:1685-1690.
29. Duncan AM, Underhill KE, Xu X, Lavalleur J, Phipps WR, Kurzer MS. Modest hormonal effects of soy isoflavones in postmenopausal women. J Clin Endocrinol Metab 1999;84:3479-3484. (Pubitemid 30645194)
30. Xu X, Duncan AM, Wangen KE, Kurzer MS. Soy consumption alters endogenous estrogen metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2000;9:781-786.
31. Reynolds K, Chin A, Lees KA, Nguyen A, Bujnowski D, He J. A meta-analysis of the effect of soy protein supplementation on serum lipids. Am J Cardiol 2006;98:633-640.
32. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones, and cardiovascular health: a summary of a statement for professionals from the American Heart Association Nutrition Committee. Arterioscler Thromb Vasc Biol 2006; 26:1689-1692. (Pubitemid 44305320)
33. Erdman JW Jr. Soy protein and cardiovascular disease: a statement for healthcare professionals from the nutrition committee of the AHA. Circulation 2000;102:2555-2559.
34. Averill MM, Bennett BJ, Rattazzi M, et al. Neither antioxidants nor genistein inhibit the progression of established atherosclerotic lesions in older ApoE deficient mice. Atherosclerosis 2009;203:82-88.
35. Adams MR, Anthony MS, Chen H, Clarkson TB. Replacement of dietary soy protein isolate with concentrates of soy 7S or 11S globulin has minimal or no effects on plasma lipoprotein profiles and biomarkers of coronary risk in monkeys. Atherosclerosis 2008;196:76-80.
36. Hooshmand S, Khalil DA, Murillo G, Singletary K, Kamath SK, Arjmandi BH. The combination of genistein and ipriflavone prevents mammary tumorigenesis and modulates lipid profile. Clin Nutr 2008;27: 643-648.
37. Lucas EA, Khalil DA, Daggy BP, Arjmandi BH. Ethanol-extracted soy protein isolate does not modulate serum cholesterol in golden Syrian hamsters: a model of postmenopausal hypercholesterolemia. J Nutr 2001;131:211-214.
38. Lucas EA, Lightfoot SA, Hammond LJ, et al. Soy isoflavones prevent ovariectomy-induced atherosclerotic lesions in golden Syrian hamster model of postmenopausal hyperlipidemia. Menopause 2003;10:314-321.
39. Guo Q, Rimbach G, Packer L. Nitric oxide formation in macrophages detected by spin trapping with iron-dithiocarbamate complex: effect of purified flavonoids and plant extracts. Methods Enzymol 2001;335: 273-282.
40. Harper A, Kerr DJ, Gescher A, Chipman JK. Antioxidant effects of isoflavonoids and lignans, and protection against DNA oxidation. Free Radic Res 1999;31:149-160.
41. Ruiz-Larrea MB, Mohan AR, Paganga G, Miller NJ, Bolwell GP, Rice-Evans CA. Antioxidant activity of phytoestrogenic isoflavones. Free Radic Res 1997;26:63-70.
42. Wei H, Bowen R, Cai Q, Barnes S, Wang Y. Antioxidant and anti-promotional effects of the soybean isoflavone genistein. Proc Soc Exp Biol Med 1995;208:124-130.
43. Rimbach G, De Pascual-Teresa S, Ewins BA, et al. Antioxidant and free radical scavenging activity of isoflavone metabolites. Xenobiotica 2003; 33:913-925.
44. Heneman KM, Change HC, Prior RL, Steinberg FM. Soy protein with and without isoflavones fails to substantially increase postprandial anti-oxidant capacity. J Nutr Biochem 2007;18:46-53.
45. Arjmandi BH, Khalil DA, Smith BJ, et al. Soy protein has a greater effect on bone in postmenopausal women not on hormone replacement therapy, as evidenced by reducing bone resorption and urinary calcium excretion. J Clin Endocrinol Metab 2003;88:1048-1054.
46. Khalil DA, Lucas EA, Juma S, Smith BJ, Payton ME, Arjmandi BH. Soy protein supplementation increases serum insulin-like growth factor-I in young and old men but does not affect markers of bone metabolism. J Nutr 2002;132:2605-2608.
47. Maskarinec G, Takata Y, Murphy SP, Franke AA, Kaaks R. Insulin-like growth factor-1 and binding protein-3 in a 2-year soya intervention among postmenopausal women. Br J Nutr 2005;94:362-367.
48. Frystyk J, Ledet T, Moller N, Flyvbjerg A, Orskiv H. Cardiovascular disease and insulin-like growth factor 1. Circulation 2002;106:893-895.
49. Juul A, Scheike T, Davidson M, Gyllenborg J, Jorgenson T. Low serum insulin-like growth factor 1 is associated with increased risk of ischemic heart disease. Circulation 2002;106:939-944.
50. Kaplan RC, Strickler HD, Rohan TE, Muzumdar R, Brown DL. Insulinlike growth factors and coronary heart disease. Cardiol Rev 2005;13: 35-39.
51. Janssen JA, Lamberts SWJ. The role of IGF-1 in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible? Eur J Endocrinol 2002;146:467-477.
52. Fischer F, Schulte H, Mohan S, et al. Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid labile subunit with coronary heart disease. Clin Endocrinol 2004;61: 595-602.
53. Ruotolo G, Bavenholm P, Brismar K, et al. Serum insulin-like growth factor is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J Am Coll Cardiol 2000;35:647-654.
54. Page JH, Ma J, Pollack M, Manson JE, Hankinson SE. Plasma insulin-like growth factor 1 and binding-protein 3 and risk of myo-cardial infarction in women: a prospective study. Clin Chem 2008;54: 1682-1688.
55. Adlercreutz H, Hockerstedt K, Bannwart C, et al. Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin (SHBG). J Steroid Biochem 1987;27:1135-1144.